Adults 18 to 65, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Self-reported Depressive Symptoms: Becks Depression Inventory-IIPrimary· At 6 months follow-up
Self-reported depressive symptoms 6 months after the ABM intervention based on a 21-item scale. Each item is scored 0-3 (where scoring description is adapted to each item), yielding a score from 0-63.
Group
Value
95% CI
Active Affective Bias Modification
19.1
± 1.7
Sham Affective Bias Modification
16.5
± 1.6
Assessment Only
5.3
± 5.5
State Rumination: Brief State Rumination Inventory (BSRI)Primary· At baseline and two weeks follow up.
Change in self-reported state rumination after the stress induction from pre to post intervention on a 8 item scale. Difference score: BSRI post intervention - BRSI Baseline. A negative score means reduction in state rumination over the intervention. Each item is scored on a 0-100 Visual Analogue Scale. The total score divided by 8 to provide the mean item total score, hence the min= 0 and max = 100 for each of the BSRI assessment time points. It was hypothesized that change in state rumination over the intervention period would mediate the effect of ABM on depressive symptoms at six months fo
Group
Value
95% CI
Active Affective Bias Modification
-.7
± 13.3
Sham Affective Bias Modification
-5.8
± 19.1
Assesment Only
-.8
± 7.4
State Rumination: Brief State Rumination InventoryPrimary· At two weeks follow up.
Self-reported state rumination after stress induction on a 8 item scale. Each item is scored on a 0-100 Visual Analogue Scale, yielding a score from 0-800, which is reported divided by 8 to provide a mean total item score. Hence the min= 0 and max = 100. A higher score indicates more state rumination.
Group
Value
95% CI
Active Affective Bias Modification
34.2
± 15.8
Sham Affective Bias Modification
32.3
± 15.8
Assessment Only
23.4
± 20.2
Affective Bias: Dot-probe TaskSecondary· From baseline to two weeks follow up
Change in reaction time in milliseconds to probes in the location of the positive facial stimuli compared to probes in the location of the negative stimuli. Positive number implies reduction in negative bias.
Group
Value
95% CI
Active Affective Bias Modification
18.0
± 28.4
Sham Affective Bias Modification
9.4
± 40.3
Symptom Network Change: Experience Sampling of Depressive SymptomsSecondary· From two weeks prior to baseline to two weeks after the two-week intervention.
Changed centrality of rumination in networks estimated based on a 9-item experience sampling questionnaire of self-reported depressive symptoms scored on a 0-100 visual analogue scale (higher value, more symptoms; reversing interest, positive affect and activity; Kraft et al., 2023, Psychiatry Research Communications). Two person-specific networks (pre and post-intervention) were estimated using the var1-function in the R package psychonetrics, with full-information maximum likelihood estimator, based on the experience sampling questionnaires that were administrated 5 times/day for 14 days bef
Group
Value
95% CI
Active Affective Bias Modification
.0175
± .0819
Sham Affective Bias Modification
-.685
± .789
Symptom Network: Experience Sampling of Depressive SymptomsSecondary· Two weeks after the two-week intervention.
Centrality of rumination in networks based on a 9-item experience sampling questionnaire of self-reported depressive symptoms scored on a 0-100 visual analogue scale (higher value, more symptoms; reversing interest, positive affect and activity; Kraft et al., 2023, Psychiatry Research Communications). Person-specific networks were estimated using the var1-function in the R package psychonetrics, with full-information maximum likelihood estimator, based on the experience sampling questionnaires that were administrated 5 times/day for 14 days after the two-week intervention. Centrality of rumina
Group
Value
95% CI
Active Affective Bias Modification
.108
± .785
Sham Affective Bias Modification
-.230
± .824
Sponsor's own description
This study evaluates the effect of a computerized intervention for depressive symptoms called Affective Bias Modification (ABM). A third of the patients will receive active ABM, a third will receive sham ABM and a third will undergo assessment only. The study will investigate if rumination mediates the effect of the intervention and investigate if specific symptom profiles affect the effect of the intervention.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
Other recruiting trials for Major Depressive Disorder
Currently open trials in the same condition.
NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC
· NA
· recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor
· Phase 2
· recruiting
NCT06749392 — An Individual-specific Synchrony Signature
· NA
· recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness
· NA
· recruiting
NCT07242105 — Optimizing Brain Excitability in Depression
· NA
· recruiting
Other University of Oslo trials
Trials by the same sponsor.
NCT07346911 — Digital Interventions for Relapse Prevention in Adolescence
· NA
· not yet recruiting
NCT07499219 — Preliminary Testing and Development of a Short Digital Intervention for Patients on Waiting Lists for Psychological Trea
· NA
· not yet recruiting
NCT07408687 — Mechanisms Of Change in Psychotherapy: The Effects of Cognitive Behavioral Therapy and Psychodynamic Therapy in Once - V
· NA
· not yet recruiting
NCT07287072 — Pain Reprocessing Therapy for Chronic Primary Pain
· NA
· not yet recruiting
NCT07428694 — From Bench to Bedside: A Machine Learning Tool for the Detection of Inspiratory Leak
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oslo
Last refreshed: 5 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04137367.